Beta Bionics, Inc. Common Stock (BBNX) Stock
Key stats
- Market cap
- $968.28M
- Price / Earnings ratio
- -10.8x
- EPS (TTM)
- -$1.83
- Volume
- Loading
- 52-week high
- $32.71
- 52-week low
- $8.80
Source: third-party data provider, as of November 13, 2026
Compare with BBNX
Recent news

BBNX Deadline Today: Rosen Law Firm Urges Beta Bionics, Inc. (NASDAQ: BBNX) Stockholders to Contact the Firm for Information About Their Rights
BBNX Deadline Today: Rosen Law Firm Urges Beta Bionics, Inc. (NASDAQ: BBNX) Stockholders to Contact the Firm for Information About Their Rights
BBNX

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Beta Bionics (NASDAQ: BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Beta Bionics (NASDAQ: BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026
BBNX

Beta Bionics 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Beta Bionics, Inc. - BBNX
Beta Bionics 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Beta Bionics, Inc. - BBNX
BBNX

Beta Bionics Q3 Earnings Call Highlights
Beta Bionics Q3 Earnings Call Highlights
BBNX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 50.96
- MACD 12/26/9
- -0.55
- EMA 9 of MACD
- -0.55
- MACD histogram
- 0.00
- SMA 50
- $18.60
- Price below SMA 50
- EMA 50
- $17.84
- Price below EMA 50
- SMA 200
- $14.80
- Price above SMA 200
- EMA 200
- $17.52
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

BBNX Deadline Today: Rosen Law Firm Urges Beta Bionics, Inc. (NASDAQ: BBNX) Stockholders to Contact the Firm for Information About Their Rights
BBNX Deadline Today: Rosen Law Firm Urges Beta Bionics, Inc. (NASDAQ: BBNX) Stockholders to Contact the Firm for Information About Their Rights
BBNX

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Beta Bionics (NASDAQ: BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Beta Bionics (NASDAQ: BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026
BBNX

Beta Bionics 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Beta Bionics, Inc. - BBNX
Beta Bionics 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Beta Bionics, Inc. - BBNX
BBNX

Beta Bionics Q3 Earnings Call Highlights
Beta Bionics Q3 Earnings Call Highlights
BBNX

Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue Estimates
Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue Estimates
BBNX

Beta Bionics, Inc. (BBNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Beta Bionics, Inc. (BBNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
BBNX

Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal
Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal
BBNX

Robbins LLP Urges BBNX Stockholders Who Lost Money Investing in Beta Bionics, Inc. to Contact the Firm for Information About Leading the Class Action
Robbins LLP Urges BBNX Stockholders Who Lost Money Investing in Beta Bionics, Inc. to Contact the Firm for Information About Leading the Class Action
BBNX

Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
BBNX

Beta Bionics, Inc. (BBNX) Surges 15.3%: Is This an Indication of Further Gains?
Beta Bionics, Inc. (BBNX) Surges 15.3%: Is This an Indication of Further Gains?
BBNX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Beta Bionics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Sean T. Saint PE | President, CEO & Director | 1976 |
| Mr. Stephen H. Feider | CFO, Treasurer & Secretary | 1990 |
| Mr. Mike Mensinger | Chief Product Officer | 1978 |
| Mr. David Henderson | Vice President of Operations | — |
| Blake Beber | Head of Investor Relations | — |
| Dr. Steven Russell M.D., Ph.D. | Chief Medical Officer | 1969 |
| Mr. Mark Hopman M.B.A., R.Ph. | Chief Commercial Officer | 1978 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 50.96
- MACD 12/26/9
- -0.55
- EMA 9 of MACD
- -0.55
- MACD histogram
- 0.00
- SMA 50
- $18.60
- Price below SMA 50
- EMA 50
- $17.84
- Price below EMA 50
- SMA 200
- $14.80
- Price above SMA 200
- EMA 200
- $17.52
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $16.00
- Average
- $24.25
- High
- $30.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | +0.8 | -7.8 | -41.7 | -1.7 | +54.8 | -22.1 | +20.4 | +14.9 | +4.5 | +34.7 | +13.1 | +3.2 |
| 2026 | -52.7 | -7.8 | -20.0 | +1.9 | +17.8 | +22.4 | -23.2 | +49.4 | -0.5 | -11.2 | +12.0 |



